阿瑞匹坦联合地塞米松磷酸钠及盐酸帕洛诺司琼预防骨肉瘤化疗后恶心呕吐的效果

黄韬; 甘雪梅; 陈明

doi:10.7619/jcmp.202005018

阿瑞匹坦联合地塞米松磷酸钠及盐酸帕洛诺司琼预防骨肉瘤化疗后恶心呕吐的效果

中国人民解放军空军军医大学附属唐都医院, 陕西西安, 710038

详细信息

中图分类号: R453
计量
- 文章访问数: 0327
- HTML全文浏览量: 0101
- PDF下载量: 010
出版历程
- 收稿日期: 2020-01-07
- 网络出版日期: 2020-08-26

Effect of aripitan combined with dexamethasone sodium phosphate and panolosetron in prevention of nausea and vomiting after chemotherapy for osteosarcoma

Tangdu Hospital Affiliated to Air Force Military Medical University of People's Liberation Army, Xi'an, Shaanxi, 710038

摘要

摘要: 目的观察阿瑞匹坦联合地塞米松磷酸钠及盐酸帕洛诺司琼在预防骨肉瘤患者应用顺铂、盐酸表柔比星联合异环磷酰胺化疗后恶心呕吐的疗效及其安全性。方法将接受骨肉瘤手术治疗且以顺铂、盐酸表柔比星联合异环磷酰胺为方案进行化疗的197例患者随机分为2组,阿瑞匹坦组(n=99)予以三联止吐方案,对照组(n=98)予以二联止吐方案。分别观察2组患者术前化疗、术后前3次化疗和术后后3次化疗0~24 h及>24~144 h内恶心呕吐的完全缓解(CR)率及不良反应的发生情况。结果术前化疗后第0~24小时,阿瑞匹坦组和对照组的完全缓解率分别为75.76%和70.41%, 差异无统计学意义(P>0.05); >24~144 h后,阿瑞匹坦组和对照组的完全缓解率分别为68.69%和54.08%, 差异有统计学意义(P<0.05)。术后前3次化疗后0~24 h, 阿瑞匹坦组和对照组的完全缓解率分别为67.68%和61.22%, 差异无统计学意义(P>0.05); >24~144 h, 阿瑞匹坦组和对照组的完全缓解率分别为59.60%和44.90%, 差异有统计学意义(P<0.05)。术后后3次化疗第0~24小时,阿瑞匹坦组和对照组的完全缓解率分别为52.53%和50.00%, 差异无统计学意义(P>0.05); >24~144 h, 阿瑞匹坦组和对照组的完全缓解率分别为46.46%和32.65%(P<0.05)。术前化疗、术后前3次化疗、术后后3次化疗时, 2组不良反应发生率均无显著差异(P>0.05), 但阿瑞匹坦组不良反应发生率略高于对照组。结论阿瑞匹坦联合盐酸帕洛诺司琼及地塞米松磷酸钠预防顺铂、盐酸表柔比星联合异环磷酰胺化疗方案对化疗0~24 h内恶心呕吐的疗效不明显,但对>24~144 h内的恶心呕吐具有显著疗效,且安全性较好,但疗效随着化疗的多次进行逐渐减弱。
- 骨肉瘤 /
- 阿瑞匹坦 /
- 化疗 /
- 恶心 /
- 呕吐
Abstract: Objective To observe the efficacy and safety of aripitan combined with dexamethasone sodium phosphate and panolosetron in preventing nausea and vomiting of patients with osteosarcoma after chemotherapy with cisplatin, epirubicin hydrochloride and ifosfamide. Methods A total of osteosarcoma patients who were given cisplatin plus epirubicin hydrochloride plus ifosfamide for chemotherapy were randomly divided into aripitan group(n=99)with triple antiemetic program and control group(n=98)with two antiemetic drug in combination. The complete response(CR)rates of nausea and vomiting and occurrence of adverse reactions at 0~24 h and >24~144 h were observed before chemotherapy, the first three times and latter three times of postoperative chemotherapies in the two groups were also observed. Results The complete remission rates in the aripitan group and control group were 75.76% and 70.41%, respectively at 0~24 h after chemotherapy, and no significant difference were observed(P>0.05), and 68.69% and 54.08%, respectively at >24~144 h, which showed significant difference(P<0.05). The complete remission rates in the aripitan group and control group were 67.68% and 61.22%, respectively at 0~24 h after the first three chemotherapies, but no significant difference were observed(P>0.05), and 59.60% and 44.90% - at >24~144 h, which showed significant difference(P<0.05). The complete remission rates in the aripitan group and control group were 52.53% and 50.00%, respectively at 0~24 h after latter three times of chemotherapies, there were no significant differences between the two groups(P>0.05), and were 46.46% and 32.65%, respectively at >24~144 h in the two groups, which showed significant difference(P<0.05). There were no differences before chemotherapy, after the first three times of chemotherapies and latter three times of chemotherapies in the incidence of adverse reactions between the two groups(P>0.05), but the incidence of adverse reactions in the aripitan group was slightly higher than that in the control group. Conclusion Aripitan combined with palonosetron hydrochloride and dexamethasone sodium phosphate has no significant effect on nausea and vomiting within 0~24 h after chemotherapy, and has a significant effect within >24~144 h. Besides, it has better efficacy, but the therapeutic effect gradually decreases with the repeated chemotherapies.
- osteosarcoma /
- aripitan /
- chemotherapy /
- nausea /
- vomiting

HTML全文

参考文献(18)

Clark-Snow R, Affronti M L, Rittenberg C N. Chemotherapy-induced nausea and vomiting(CINV)and adherence to antiemetic guidelines: results of a survey of oncology nurses[J]. Support Care Cancer, 2018, 26(2): 557-564.

Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice[J]. Nat Clin Pract Oncol, 2008, 5(1): 32-43.

徐波. 化学治疗所致恶心、呕吐的护理指导[M]. 北京: 人民卫生出版社, 2015: 112-116.

Chou A J, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions[J]. Expert Rev Anticancer Ther, 2006, 6(7): 1075-1085.

Wang S Y, Yang Z J, Zhang Z, et al. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy [J]. Asian Pac J Cancer Prev, 2014, 15(23): 10045-10051.

牛晓辉, 黄真, 张清. 软组织肉瘤化疗的研究现状[J]. 山东医药, 2011, 51(40): 46-47.

Davis M P. New therapies for antiemetic prophylaxis for chemotherapy[J]. J Community Support Oncol, 2016, 14(1): 11-20.

Rojas C, Slusher B S. Pharmacological mechanisms of 5-HT₃ and tachykinin NK receptor antagonism to prevent chemotherapy-induced nausea and vomiting[J]. Eur J Pharmacol, 2012, 684(1/2/3): 1-7.

Rojas C, Raje M, Tsukamoto T, et al. Molecular mechanisms of 5-HT(3)and NK(1)receptor antagonists in prevention of Emesis[J]. Eur J Pharmacol, 2014, 722: 26-37.

王丽, 杜艳丽, 江泽莹, 等. 自我效能干预联合药物治疗化疗性呕吐的研究[J]. 护理学杂志: 综合版, 2015(7): 41-43.

Takahashi T, Hoshi E, Takagi M, et al. Multicenter, phase Ⅱ, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin[J]. Cancer Sci, 2010, 101(11): 2455-2461.

黄鲁众, 张晓晔, 刘艳, 等. 阿瑞匹坦联合5-HT3受体拮抗剂和地塞米松预防化疗相关性恶心和呕吐的Meta分析[J]. 现代肿瘤医学, 2015, 23(15): 2198-2203.

赵桂芳, 熊杰, 叶挺, 等. 阿瑞匹坦预防阿霉素联合异环磷酰胺方案化疗后呕吐的临床观察[J]. 肿瘤学杂志, 2017, 23(9): 802-806.

宫晨, 熊华, 王建华, 等. 阿瑞匹坦对骨与软组织肉瘤患者强致吐风险化疗相关性呕吐的预防效果[J]. 医药导报, 2016, 35(11): 1198-1201.

苏丹, 赵水喜, 曹京旭. 阿瑞匹坦预防化疗引起恶心呕吐的疗效及安全性[J]. 武警医学, 2016, 27(9): 871-873.

丁海水. 不同剂量帕洛诺司琼用于预防腹腔镜下胆囊切除术后恶心呕吐的临床观察[J]. 江西医药, 2015, 50(11): 1274-1276.

徐燕, 计张奕, 李玉芳. 泮托拉唑联合帕洛诺司琼防治肿瘤患者化疗所致胃肠道反应的疗效观察[J]. 临床合理用药杂志, 2016, 9(28): 42-43.

孔翔, 高淑红, 林红梅. 帕洛诺司琼联合地塞米松预防术后恶心呕吐的Meta分析[J]. 中国当代医药, 2015, 22(25): 4-7

, 11.